anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Psychological stress response refers to the negative emotional states generated when an individual perceives that they do not have the resources to cope with or respond to a threat. Low back pain (LBP) is a complex condition with multiple contributors, including psychological factors. However, whether LBP is a stressor that causes a psychological stress response remains unknown. This study aimed to investigate the association between LBP and psychological stress response in a Japanese population-based cohort.
METHODS: Participants aged >50 years were recruited from inhabitants of a mountain village in Japan. The participants completed the following patient-reported outcome measures. The extent of the psychological stress response was measured using the Stress response scale (SRS)-18, which includes the subscales "Depression/Anxiety", "Irritability/Anger", and "Helplessness". LBP intensity in several situations/positions was measured using a numerical rating scale (NRS). Quality of life (QOL) was measured using the Oswestry Disability Index, EuroQol 5-dimension, and EuroQol visual analog scales. The association between SRS-18 and each parameter was statistically evaluated.
RESULTS: A total of 282 participants (72.1 years old) were analyzed in this study, and 29.1% had chronic LBP. The SRS-18 total score of all participants ranged from 0 to 43, and the average SRS-18 total score was 7.7 ± 8.8 (depression/anxiety: 2.3 ± 3.2, irritability/anger: 2.4 ± 3.3, helplessness: 2.9 ± 3.2). SRS-18 scores of participants with LBP were significantly higher than those of participants without LBP. SRS-18 scores were significantly correlated with QOL scores (P < 0.01, correlation coefficient = 0.22-0.46). Multiple regression analysis showed that the NRS score of LBP during morning awakening was significantly associated with the SRS-18 total, depression/anxiety, and helplessness scores.
CONCLUSIONS: Psychological stress responses were associated with LBP and LBP-related QOL among residents of a Japanese mountain village.
Participants will receive one capsule of the marketed reference containing Oseltamivir 75 mg. The capsules will be taken with water and in a fasting condition.
In the high-intensity aerobic exercise group, exercise training was performed on a motorized treadmill with occasional substitution with the elliptical machine as needed for joint pain. Target heart rate was based on the baseline treadmill test and was calculated as percentage of the heart rate reserve (HRR=maximal HR-resting HR). Initially, participants trained for 20-30 minutes at 50-60% of HRR. Duration and intensity was increased by 10% weekly so that within 5-7 weeks the aerobic exercise sessions lasted 30-45 minutes at 70-85% of HRR and at the end of the 16 weeks lasted 40-45 minutes at 75-90% of HRR.
Dysfunction of the sympathetic nervous system and increased epicardial adipose tissue (EAT) have been independently associated with the occurrence of cardiac arrhythmia. However, their exact roles in triggering arrhythmia remain elusive. Here, using an in vitro coculture system with sympathetic neurons, cardiomyocytes, and adipocytes, we show that adipocyte-derived leptin activates sympathetic neurons and increases the release of neuropeptide Y (NPY), which in turn triggers arrhythmia in cardiomyocytes by interacting with the Y1 receptor (Y1R) and subsequently enhancing the activity of the Na+/Ca2+ exchanger (NCX) and calcium/calmodulin-dependent protein kinase II (CaMKII). The arrhythmic phenotype can be partially blocked by a leptin neutralizing antibody or an inhibitor of Y1R, NCX, or CaMKII. Moreover, increased EAT thickness and leptin/NPY blood levels are detected in atrial fibrillation patients compared with the control group. Our study provides robust evidence that the adipose-neural axis contributes to arrhythmogenesis and represents a potential target for treating arrhythmia.
1. A phosphate composition comprising phosphorus acid, iron, metal powder, for example, Zn or Mn powder, characterized in that comprises iron in the form of iron oxide and metal powder in the form of powder of any metal, having the following ratio of components, %wt: orthophosphorus acid 100 iron oxide 20-41 metal powder 0.5-2.5 water 30-70 2. Utilization of phosphate composition of Claim 1 as a disinfectant in products, used in medicine and veterinary and having antimicrobial, antivirus and fungicidal properties. 3. Utilization of phosphate composition of Claim 1 in pharmacology to prepare medicaments against inflammatory and fungous diseases. 4. Utilization of phosphate composition of Claim 1 in agriculture as a means of curing plant diseases. 5. Utilization of phosphate composition of Claim 1 as a adhesive binding of cold solidification to obtain fire-resistant, anticorrosive, decorative, hydro-electric isolating covers, anti-radiation coatings without thermal treatment.
The invention discloses an enteric dry suspension of rabeprazole and dextroisomer thereof, and a preparation method thereof, and belongs to the technical field of medicines. The enteric dry suspension is composed of 30-59% by weight of rabeprazole enteric microspheres, 40-69% by weight of a corrective agent and 1-30% by weight of a suspending aid. Sustained-release microspheres A are prepared by a rabeprazole salt and a sustained-release skeleton material through a hot-melt spray method; the sustained-release microspheres A are coated by an isolation coating layer and an enteric coating layer in sequence; and then the sustained-release microspheres A are mixed with the corrective agent and the suspending aid. The prepared enteric dry suspension of rabeprazole and dextroisomer thereof is dispersed uniformly in intestinal tracts, and does not produce burst release. Compared with tablets or capsules, the enteric dry suspension has good stability, is convenient to separate dosage, is taken by adding water to form a solution, is good in absorptive capacity, fast in efficacy and good in bioavailability, has a good taste, is particularly suitable for patients suffering from difficult swallowing, especially for infant patients, and increases compliance of the patients. Besides, the preparation method is simple and is suitable for large-scale production and application.
The invention discloses a semen cassiae, fructus lycii and glossy privet fruit oral solution with functions of tonifying liver and reducing fat. The semen cassiae, fructus lycii and glossy privet fruit oral solution is prepared by adopting the steps of respectively weighing Chinese medicinal herbs: 30 parts of semen cassia, 30 parts of fructus lycii, 30 parts of glossy privet fruit, 20 parts of polygonum multiflorum thumb, 20 parts of gynostemma pentaphylla, 20 parts of raw hawthorn, 20 parts of capillary artemisia, 10 parts of radix curcumae and 10 parts of rhizoma alismatis; and decocting the Chinese medicinal herbs together according to a conventional method, and densely decocting into an oral solution of 2g dried medicinal herbs/ml. A taking method is as follows: the semen cassiae, fructus lycii and glossy privet fruit oral solution is taken twice, 20ml per time. One month is a course of treatment, and the semen cassiae, fructus lycii and glossy privet fruit oral solution is generally taken for three courses of treatment. Fatty, sweet, stodgy and pungent foods are contraindicated in a taking process. The semen cassiae, fructus lycii and glossy privet fruit oral solution has the advantages of low Chinese medicinal herb price, and is convenience to take and process, and has a remarkable treatment effect on non-alcoholic fatty liver disease and hyperlipoidemia. Meanwhile, according to the characteristic of liver deficiency, the semen cassiae, fructus lycii and glossy privet fruit oral solution is suitable for all types of syndrome of the traditional Chinese medicine, is capable of recovering the function of the liver to protect the liver and is capable of removing pathological products to achieve the treatment purpose.
Provided herein are multiple solid forms of a defined steroid-like compound, and methods for the preparation and use thereof. In one aspect, there is provided a crystalline form of said steroid-like compound, and methods for the preparation and use thereof. In another aspect, there is provided a substantially amorphous form of said steroid-like compound, and methods for the preparation and use thereof. In yet another aspect, there are provided compositions containing compounds according to the present invention. In certain aspects, such compositions are suitable for delivery of active agents according to the present invention to a subject in need thereof. In another aspect of the invention, there are provided methods for the treatment of a variety of indications, including glaucoma, ocular hypertension, and the like. In still another aspect of the present invention, there are provided kits containing compounds according to the present invention and/or compositions containing same.
Rationale: COPD patients are largely asymptomatic until the late stages when prognosis is generally poor. In this study, we shifted the focus to pre-COPD and smoking stages, and found enrichment of hypoxia inducible factor (HIF)-3α is in pre-COPD samples. Smoking induced regional tissue hypoxia and emphysema have been found in COPD patients. However, the mechanisms underlying hypoxia especially HIF-3α and COPD have not been investigated. Methods: We performed bulk-RNA sequencing on 36 peripheral lung tissue specimens from non-smokers, smokers, pre-COPD and COPD patients, and using "Mfuzz" algorithm to analysis the dataset dynamically. GSE171541 and EpCAM co-localization analyses were used to explore HIF-3α localization. Further, SftpcCreert2/+R26LSL-Hif3a knock-in mice and small molecular inhibitors in vitro were used to explore the involvement of HIF-3α in the pathophysiology of COPD. Results: Reactive oxygen species (ROS) and hypoxia were enriched in pre-COPD samples, and HIF-3α was downregulated in alveolar epithelial cells in COPD. In vitro experiments using lentivirus transfection, bulk-RNA seq, and RSL3 showed that the activation of the HIF-3α-GPx4 axis inhibited alveolar epithelial cell ferroptosis when treated with cigarettes smoking extracts (CSE). Further results from SftpcCreert2/+R26LSL-Hif3a knock-in mice demonstrated overexpression of HIF-3α inhibited alveolar epithelial cells ferroptosis and prevented the decline of lung function. Conclusion: Hypoxia and oxidation-related damage begins years before the onset of COPD symptoms, suggesting the imbalance and impairment of intracellular homeostatic system. The activation of the HIF-3α-GPx4 axis is a promising treatment target. By leveraging this comprehensive analysis method, more potential targets could be found and enhancing our understanding of the pathogenesis.
Lymphoma is a highly heterogeneous lymphohematopoietic tumor. As our understanding of the biological and pathological characteristics of lymphoma improves, we are identifying an increasing number of lymphoma subtypes. Genotyping has enhanced our ability to diagnose, treat, and monitor the prognosis of lymphoma. Despite significant improvements in treatment effectiveness, traditional methods for assessing disease response and monitoring prognosis are imperfect, and there is no significant improvement in overall remission rates for lymphoma patients. Minimal Residual Disease (MRD) is often indicative of refractory disease or early relapse. For lymphoma patients, personalized MRD monitoring techniques offer an efficient means to estimate disease remission levels, predict early relapse risk, and assess the effectiveness of new drug regimens. In this review, we delve into the MRD procedures in lymphoma, including sample selection and requirements, detection methods and their limitations and advantages, result interpretation. Besides, we also introduce the clinical applications of MRD detection in lymphoma.
Microtablets comprise a compacted mixt. of active agents and auxiliaries and have a diameter of at most 3mm. Tablet comprises (a) vegetable active agents in the form of at least one dry vegetable extract which makes up 30 wt. % of the total wt. of the tablet, and (b) at least one lipophilic auxiliary selected from glycerides, fatty alcohols and waxes. USE/ADVANTAGE - The neurotablets can be used as phytopharmaceuticals in multi-unit-dose systems. They can be filled into hard gelatin capsules with conventional filling machines.
BACKGROUND: Risperidone is an atypical antipsychotic drug used to treat irritability and aggression in children and adolescents with autism spectrum disorder. In an earlier study, the sum trough concentration of risperidone and its metabolite (9-hydroxyrisperidone) was positively correlated with weight gain and effectiveness. The aim of this study was to determine the therapeutic window for risperidone sum trough concentrations that balances weight gain with treatment effectiveness in this population. In addition, the effect of therapeutic drug monitoring (TDM) on treatment optimization was simulated.
METHODS: In a retrospective cohort (n = 24 children), the target window for risperidone leading to the least increase in body mass index z-scores while retaining effectiveness as measured by the irritability subscale of the Aberrant Behavior Checklist was determined using receiver operating curve analysis. This target range was used to simulate the effect of TDM using a population PK model implemented in the software platform InsightRX. Dosing advice was based on plasma trough concentrations and the dose administered at 12 weeks to simulate whether more children would be on target at 24 weeks after the start of treatment.
RESULTS: A risperidone sum trough target range of 3.5-7.0 mcg/L would minimize increase in body mass index z-score and optimize effectiveness. Dosing advice using TDM and a population PK model would lead to a larger proportion of children achieving the target concentration range (62.5% versus 16.7%).
CONCLUSIONS: TDM may be a useful tool for optimizing risperidone treatment in children and adolescents with autism spectrum disorder.
Restylane and Perlane administered by injection. Recommended volume of 6.0 mL. Injection on study day 1 with an optional touch up on study day 14.
The use of trinitrotoluene (TNT) for preparation of a bloodvessel relaxing and dilating agent is new. The effect on blood vessel muscle can be detected at levels of TNT as low as 10power-15 molar. In an example: Bovine arterial material was recovered within 30 minutes of slaughter and maintained in a physiological buffer soln. 5mm long samples, fat removed were mounted on a tension measuring device in an organ bath. The tissue was contracted with 3 micromols phenylephrin (an adrenalin like material). (Provisional Basic previously advised in Week 9115) @(7pp Dwg.No.0/2)
Although endoscopic necrosectomy (EN) is more frequently used to manage walled-off necrosis (WON), there is still debate over how much time should pass between the initial stent placement and the first necrosectomy. This study aims to determine the effect of performing EN within different timings after placing the initial stent on clinical outcomes for WON. A retrospective study on infected WON patients compared an early necrosectomy within one week after the initial stent placement with a necrosectomy that was postponed after a week. The primary outcomes compared the rate of clinical success and the need for additional intervention after EN to achieve WON resolution. 77 patients were divided into early and postponed necrosectomy groups. The complete resolution of WON within six months of follow-up was attained in 73.7% and 74.3% of patients in both the early and postponed groups. The early group tended to a greater need for additional intervention after EN (26.8% early necrosectomy vs. 8.3% postponed necrosectomy, P = 0.036). Our study does not demonstrate that early necrosectomy is superior to postponed necrosectomy in terms of clinical success rate, total count of necrosectomy procedures, procedure-related complications, length of hospitalization and prognosis. Conversely, patients in the postponed group received fewer additional interventions.
Uric acid is a toxin retained with advancing kidney disease. Clinical manifestations of hyperuricemia include gout and systemic inflammation that are associated with increased risk of cardiovascular mortality. As many as one-third of all patients with chronic kidney disease have a history of gout, yet <25% of these patients are effectively treated to target serum urate levels of ≤6 mg/dl. A major reason for ineffective management of gout and hyperuricemia is the complexity in managing these patients, with some medications contraindicated and others requiring special dosing, potential drug interactions, and other factors. Consequently, many nephrologists do not primarily manage gout despite it being a common complication of chronic kidney disease, leaving management to the primary physician or rheumatologist. We believe that kidney specialists should consider gout as a major complication of chronic kidney disease and actively manage it in their patients. Here, we present insights from nephrologists and rheumatologists for a team approach to gout management that includes the nephrologist.
Patients who met the inclusion criteria, did not meet the exclusion criteria, and agreed to accept the treatment plan of this study will undertake a combination chemotherapy regimen, comprised of serplulimab (300mg), etoposide (100 mg/m2), and carboplatin (AUC 5 mg/mL/min, up to 750mg). These agents will be administered intravenously in 3-week intervals over a span of 4 to 6 cycles.
Matching placebo capsules for oral administration. Placebo capsules will be administered as 5 capsules thrice daily (15 capsules per day total) to each of two subject cohorts based on estimated glomerular filtration rate (eGFR). Treatment Period is 14 Days.
Dementia is a neurodegenerative disease characterized by cognitive dysfunction affecting aspects of memory and learning. Although the mechanisms that underlie the pathophysiology of dementia are still unclear, in the past decade there has been a focus on the adverse impact of sleep disturbance on brain waste disposal via the glymphatic system. The glymphatic system is a recently discovered brain-wide perivascular passageway that transports toxic neuro-metabolites (e.g.: amyloid beta, or Aβ) out of the brain to the blood via the cerebrospinal fluid. Newer research has shown that the glymphatic system becomes particularly active during sleep, clearing metabolites twice as fast compared with wakefulness. Obstructive sleep apnea (OSA), a sleep disorder characterized by periods of intermittent hypoxia and sleep fragmentation due to obstructed breathing, has traditionally been causatively linked to the development of hypertension and cognitive dysfunction. Further to this, recent epidemiological studies have also linked OSA to an increased risk for both dementia and its prodromal state - mild cognitive impairment. There is emerging evidence to suggest that OSA might chronically impair glymphatic clearance of Aβ42 from the brain and facilitate the formation of Aβ plaques that characterize Alzheimer's Disease.

Recent ground-breaking research has shown that clearance of toxic neuro-metabolites from the brain including the proteins Aβ and tau that form dementia causing plaques and tangles is markedly impaired when sleep is disturbed. This suggests that dementia risk may be increased in people with sleep disorders such as OSA. Longitudinal studies have linked OSA with a 70-85% increased risk for mild cognitive impairment and dementia.

Despite this strong link, little is known about the OSA-specific mechanistic underpinnings. It is not fully understood as to how sleep disturbance in OSA inhibit brain glymphatic clearance. However, it is known that OSA inhibits slow wave sleep, profoundly activates sympathetic activity, and elevates blood pressure - particularly during sleep. These disturbances have, in turn, been shown to independently inhibit glymphatic function. Previous studies have attempted to sample human cerebrospinal fluid (CSF) involved in glymphatic clearance for dementia biomarkers during sleep. However, these studies were severely limited by the need for invasive CSF sampling. To address this problem, this proposed study will use a set of newly available, highly sensitive blood based SIMOA assays to study glymphatic function in people treated for severe OSA who undergo CPAP withdrawal. Furthermore, novel methods will be utilized to capture changes in slow wave sleep, blood pressure and brain blood flow together with sleep-wake changes in blood levels of excreted neuro-metabolites to define the pathophysiological mechanisms that inhibit brain cleaning in OSA.
All participants entered into the study will undergo at least one cranial scanning using the InfraScanner 2000 within 4 hours before or after CT scan. Patients will know the results of the CT scan but not of the InfraScanner 2000. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative.
The invention provides a Chinese herbal medicinal composition for treating condyloma acuminatum and a preparation method thereof. The composition comprises the following Chinese herbal medicinal raw materials in parts by weight: 20 to 40 parts of bamboo shoot, 20 to 40 parts of climbing groundsel herb, and 10 to 30 parts of whiteflower leadword root. The preparation method comprises the following steps: baking Chinese herbal medicaments; pulverizing or crushing; leaching; concentrating; drying; and mixing to prepare oral solution, granules, tablets, powder and capsules. The Chinese herbal medicinal composition has rich drug sources, simple preparation process and low cost. Clinical tests prove that: the wart stops growing and necrotizes after a patient takes the composition for 10 days; the wart falls and is completely healed after the patient takes the composition for 20 days, protective immunity is generated in the body, and the surface part of the focus is completely repaired; and a critically ill patient can be completely healed when taking less than 50 days, and does not relapse. The effective rate is 92 percent, and the cure rate is 81 percent. The Chinese herbal medicinal composition has quick treatment effect, safety and reliability and no adverse reaction, and has remarkable effects in effectively inhibiting wart growth and complete heal.
Understanding mechanisms leading to decrements in lung function, the physiologic hallmark of obstructive lung diseases including chronic obstructive pulmonary disease (COPD), are necessary to inform interventions to improve lung health. The antimicrobial peptide cathelicidin, and its primary regulator vitamin D, has been implicated in development and progression of chronic lung disease. In this study, the investigators will evaluate the effect of oral vitamin D supplementation on lung cathelicidin levels in humans. Cathelicidin has bactericidal and inflammatory activities in the lung and is regulated by vitamin D levels. The investigators hypothesize that oral vitamin D supplementation will raise cathelicidin levels in the pulmonary compartment, thereby restoring lung cathelicidin deficiency. To test this hypothesis, the investigators will recruit from two ongoing cohort studies: 1) At Johns Hopkins, the Subpopulations and Intermediate Outcome Measures in COPD Study study and 2)at University of North Carolina at Chapel Hill pulmonary and general medicine clinic. The investigators will measure blood and lung lavage cathelicidin levels in 40 vitamin D insufficient individuals (20 from each cohort) before and after eight weeks of oral vitamin D supplementation to determine the effect of vitamin D supplementation on cathelicidin levels.